Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17

Experimental and Therapeutic Medicine

Volumn 9, Issue 6, 2015, Pages 2047-2052

  Kleiner, Giulio ^a   Zanin, Valentina ^a   Monasta, Lorenzo ^a   Crovella, Sergio ^a,b   Caruso, Lorenzo ^c   Milani, Daniela ^c   Marcuzzi, Annalisa ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Chemokines; Cytokines; Inflammatory bowel disease

Indexed keywords

CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INHIBITORY PROTEIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NERVE GROWTH FACTOR BETA SUBUNIT; RANTES; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADOLESCENT; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNOASSAY; INFANT; INFLAMMATORY BOWEL DISEASE; MALE; PEDIATRICS; PROTEIN ANALYSIS;

EID: 84928254122     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2370     Document Type: Article

References (35)

1. Podolsky DK: Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
2. Scaldaferri F and Fiocchi C: Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 8: 171-178, 2007.
3. Sartor RB: Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407, 2006.
4. Raza A, Yousaf W, Giannella R and Shata MT: Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol 8: 161-168, 2012.
5. Cassinotti A, Sarzi-Puttini P, Fichera M, Shoenfeld Y, de Franchis R and Ardizzone S: Immunity, autoimmunity and inflammatory bowel disease. Autoimmun Rev 13: 1-2, 2014.
6. Geremia A, Biancheri P, Allan P, Corazza GR and Di Sabatino A: Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13: 3-10, 2014.
7. Kleiner G, Marcuzzi A, Zanin V, Monasta L and Zauli G: Cytokine levels in the serum of healthy subjects. Mediators Inflamm 2013: 434010, 2013.
8. Spray C, Debelle GD and Murphy MS: Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. Acta Paediatr 90: 400-405, 2001.
9. Heikenen JB, Werlin SL, Brown CW and Balint JP: Presenting symptoms and diagnostic lag in children with inflammatory bowel disease. Inflamm Bowel Dis 5: 158-160, 1999.
10. Lewis JD: The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 140: 1817-1826, 2011.
11. Volpato S, Ferrucci L, Secchiero P, et al: Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 215: 452-458, 2011.
12. Tisato V, Zauli G, Voltan R, et al: Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PLoS One 7: e39543, 2012.
13. Tisato V, Zamboni P, Menegatti E, et al: Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease. Cytokine 63: 92-96, 2013.
14. Neurath MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol 14: 329-342, 2014.
15. Francescone R, Hou V and Grivennikov SI: Cytokines, IBD, and Colitis-associated Cancer. Inflamm Bowel Dis 21: 409-418, 2015
16. Wallace KL, Zheng LB, Kanazawa Y and Shih DQ: Immunopathology of inflammatory bowel disease. World J Gastroenterol 20: 6-21, 2014.
17. Jiang W, Su J, Zhang X, Cheng X, Zhou J, Shi R and Zhang H: Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 63: 943-950, 2014.
18. Dinarello CA: Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 360: 2467-2470, 2009.
19. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S and Schreiber S: Increased expression of IL-16 in inflammatory bowel disease. Gut 48: 326-332, 2001.
20. Marion R, Coëffier MM, Gargala G, Ducrotté P and Déchelotte PP: Glutamine and CXC chemokines IL-8, Mig, IP-10 and I-TAC in human intestinal epithelial cells. Clin Nutr 23: 579-585, 2004.
21. Damen GM, Hol J, de Ruiter L, et al: Chemokine production by buccal epithelium as a distinctive feature of pediatric Crohn disease. J Pediatr Gastroenterol Nutr 42: 142-149, 2006.
22. Mayer L, Sandborn WJ, Stepanov Y, et al: Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 63: 442-450, 2014.
23. Del Zotto B, Mumolo G, Pronio AM, Montesani C, Tersigni R and Boirivant M: TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin Exp Immunol 134: 120-126, 2003.
24. Watanabe M, Ueno Y, Yajima T, et al: Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest 95: 2945-2953, 1995.
25. Seow CH, Benchimol EI, Griffiths AM and Steinhart AH: Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3: CD006790, 2008.
26. Mazzucchelli L, Hauser C, Zgraggen K, et al: Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J Pathol 178: 201-206, 1996.
27. Grimm MC and Doe WF: Chemokines in inflammatory bowel disease mucosa: Expression of RANTES, macrophage inflammatory protein (MIP)-1α, MIP-1β and γ-interferon-inducible protein-10 by macrophages, lymphocytes, endothelial cells and granulomas. Inflamm Bowel Dis 2: 88-96, 1996.
28. Banks C, Bateman A, Payne R, Johnson P and Sheron N: Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 199: 28-35, 2003.
29. Katz LH, Kopylov U, Fudim E, et al: Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. Clin Res Hepatol Gastroenterol 38: 491-498, 2014.
30. Ueno A, Jijon H, Chan R, et al: Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis 19: 2522-2534, 2013.
31. Fitzpatrick LR: Inhibition of IL-17 as a pharmacological approach for IBD. Int Rev Immunol 32: 544-555, 2013.
32. Tillack C, Ehmann LM, Friedrich M, et al: Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63: 567-577, 2014.
33. Monteleone I, Sarra M, Pallone F and Monteleone G: Th17-related cytokines in inflammatory bowel diseases: friends or foes? Curr Mol Med 12: 592-597, 2012.
34. Bianco AM, Girardelli M, Vozzi D, Crovella S, Kleiner G and Marcuzzi A: Mevalonate kinase deficiency and IBD: shared genetic background. Gut 63: 1367-1368, 2014.
35. Marcuzzi A, Girardelli M, Bianco AM, Martelossi S, Magnolato A, Tommasini A and Crovella S: Inflammation profile of four early onset Crohn patients. Gene 493: 282-285, 2012.